Welcome to Entry Card of Peptide


Details of TopicalPdb ID 1114

PRIMARY INFORMATION
ID1114
PMID19709343
Year2009
SequenceFLGGLIKIVPAMICA
VTKKC
NameRanalexin
Length20
N-Terminal ModificationFree
C-Terminal ModificationFree
Linear/ CyclicLinear
ChiralityL
Chemical ModificationNone
Origin of PeptideNorth American bullfrog, Rana catesbeiana
Nature of Peptide/CargoAntimicrobial
MechanismRanalexin and lysostaphin have enhanced bactericidal efficacy in combination compared to the agents used alone in vitro.The cationic loop and hydrophobic tail shared by Ranalexin and polymyxin could represent a fundamental membrane-permeabilizing peptide motif more widely utilized in nature
Cargo Sequence/StructureAETTNTQQAHTQMSTQSQDVSYGTYYTIDSNGDYHHTPDGNWNQAMFDNKEYSYTFVDAQGHTHYFYNCYPKNANANGSGQTYVNPATAGDNNDYTASQSQQHINQYGYQSNVGPDASYYSHSNNNQAYNSHDGNGKVNYPNGTSNQNGGSASKATASGHAKDASWLTSRKQLQPYGQYHGGGAHYGVDYAMPENSPVYSLTDGTVVQAGWSNYGGGNQVTIKEANSNNYQWYMHNNRLTVSAGDKVKAGDQIAYSGSTGNSTAPHVHFQRMSGGIGNQYAVDPTSYLQSR
Name of cargo
Lysostaphin
AssayFranz diffusion cell
EnhancerNone
Properties of enhancerNot applicable
Concentration10 µl MRSA252 suspension (1·108 CFU ml -1) which was allowed to dry at 25°C; 30 min, 50µl of a treatment solution made up in PBS (100 mg l-1) ranalexin and (1 mg l-1) lysostaphin
Incubation time30 minutes
Tissue permeability (value with units)In combination these compounds reduced viable bacteria by 2.83 ± 0.26 log10 CFU
Tissue SampleAbdominal skin from a 38-year-old white female donor
Ex vivo/In vivo/In vitroex vivo
SECONDARY INFORMATION
STRUCTURE
Predicted Structure
SMILESN[C@@H](Cc1ccccc1)C(=O)N[C@@H]
(CC(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)
N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCC[NH3])C(=O)
N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)
N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)
C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]
(CS)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)
N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCC[NH3])
C(=O)N[C@@H](CCCC[NH3])C(=O)N[C@@H](CS)C=O